Patients recovery with HIV/AIDS in Botswana / Africa, with the use of the homeopathic Medicine Canova (2006)

Canova is a homeopathic complex medicine used as an immune modulator. Botswana has the highest prevalence of Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS) in the world. Objective: Evaluate the longitudinal evolution in HIV/AIDS patients’ quality of life, which only use Canova®. This work was intended to be a prospective study.

Year of publication: 2006

in: UFPR

Click here to download this work in PDF

The Use of Immunomodulators in Asthma Treatment (2006)

The general aim of this study is to evaluate the effectiveness of immunomodulator Canova® and the paradigms of development of asthma episodes in patients bearing this disease in the ambulatory of the Medical Clinic in the city of Riachinho/ MG.

Year of publication: 2006

Click here to download this work in PDF

HIV/AIDS+ patients treated with the homeopathic Medicine Canova: Prospective Observational study in Laboratory, Clinical and of Quality of Life Indexes (2005)

This study evaluated the longitudinal evolution of patients HIV/AIDS+, after one month and after six months of use of the medicine Canova®, concomitant or not with the use of conventional medicines. It demonstrated that the treatment allows an improvement in the following parameters: increase of the appetite and of the available energy for daily routine, decrease of the pain and depression, opportunistic infections decrease, increase of the n° of lymphocytes CD4 and of the total n° of erythrocytes, thus improving the quality of life.

Year of publication: 2005

in: UFPR

Click here to download this work in PDF

Quality of life and handling of Cancer or Aids with Immunomodulator Canova® (2004)

The treatment with Immunomodulator Canova® is appointed by the patients who underwent the treatment as medical behavior that makes possible the longer life and the improvement of life quality. The patients before the treatment present significant limitations in the accomplishment of routine activities [sleepiness, alimentation, pain, leisure, sexual activity, work]. Generally they find themselves in terminal phase, with limitations or impossibilities to practice any physical activity without discomfort and pain, and in whom the conventional clinical treatment is little effective. After the beginning of the treatment with Immunomodulator Canova®, the patient is not free of an intense and rigid medical routine, because he remains dependent of the continued use of the medicament and periodic clinical return always followed by lucidation examinations, laboratory and image diagnosis, in order to guarantee the contention control of the illness.

Year of publication: 2004

Click here to download this work in PDF

Immunomodulator Canova® – Aids and quality of life. (2002)

Immunomodulator Canova® showed to be efficient and of easy acceptability. There was 100% of adhesion of the patients to the treatment with Immunomodulator Canova®, with the results showed previously. For us from the DST/Aids it is rewarding to follow up the evolution and the patient’s enthusiasm treated with Canova® after the results obtained during this study work.

Year of publication: 2002

Click here to download this work in PDF

Clinical study for the evaluation of Immunomodulator Canova® in the therapeutics of oncologic patients considered OTP – Out of Therapeutic Possibility. (2002)

The present study evidenced in the clinical field Immunomodulator Canova® therapeutic effectiveness in oncologic patients and Out of Therapeutic Possibilities. The medicine showed to be a weapon of quite useful use in the institution of the palliative cares, for its actions, observed in this study, in relation to the significant improvement of the general health conditions, gaining of weight, reduction of nauseas and vomits, decrease of asthenia and increase of the patients’ willingness due to the new vitality observed from the moment that the patients themselves noticed their clinical improvement, besides the adverse effects have not been evidenced. New studies should be accomplished for deep investigation, statistics and better understanding of these presented clinical results, as well as about the possible action in the reduction of the value of the tumor markers. Thus, while we are completely waiting for an effective anti-neoplasm medicine, we will be able to at least increase the dignity conditions in the continuation of the oncologic disease.

Year of publication: 2002

Click here to download this work in PDF

Randomized Placebo-Controlled Clinical Trial to appraise the effectiveness and safety of Immunomodulator Canova® in the therapeutics of patients who have HIV/AIDS on anti-retroviral use. (2001)

The present placebo-controlled randomized clinical study demonstrated the effectiveness of the medicament called Immunomodulator Canova® in the therapeutics of patients who have AIDS, on anti-retroviral use. Due to the decrease of the viral load, opportunistic diseases, toxicity effects and general organic improvement, there was an improvement in the quality of life.

Year of publication: 2001

Click here to download this work in PDF

A Multicentric Clinical Survey of HIV/AIDS patients submitted to Canova Immunomodulator® treatment associated with Antiretrovirus Medicaments. (2002)

Individuals infected by HIV may have a greater life, associated with an increase in the life quality through his/her reintegration to the society, harmoniously working and spending some time in leisure, with the decrease of the morbidity/mortality, and defined by the infection of HIV. The study work suggests a need of more research in new appraised study works for statistical analyses.

Year of publication: 2001

Click here to download this work in PDF

Evaluation of Canova® Immunomodulator use in patients with cancer. (2003)

The daily clinic plus the present study showed that the treated patients with the homeopathic medicine Immunomodulator Canova®, concomitant with conventional therapies presented decrease of the pain complaints, improvement of appetite and of the cognitive function already in the beginning of the treatment; it improves that constant during the whole appraised period. The possibility of physical activity was a consequence of the improvement of life quality and it provided an improvement of the observed self-esteem during the treatment. The evolution of the Karnofsky Performance Index shows with clarity that a medication without toxicity and/or collateral effects, acting on the defenses of the body becomes indispensable to the modern therapeutic arsenal. This Effectiveness was also demonstrated in the results of the accomplished biochemical exams. We noticed, yet, in most of the patients, the significant decrease of tumor volumes, after the therapy with Immunomodulator Canova®. That fact brought to the discussion the possibility to use, again, invasive therapies, surgeries or even in the restarting the cycles of chemotherapies, which were stopped. Another verified fact was the high adhesion index to the treatment with Canova®, where the patients attended spontaneously in search of the treatment and for the continuity of the medication. Even in those where there was partial or total tumor mass resolution to the image exam, the interest of going on taking the medication was unanimous. The homeopathic medicines compound Immunomodulator Canova® showed to be an effective procedure when rescuing therapeutic forms that can guarantee longer life with better life quality.

Year of publication:

Click here to download this work in PDF